Managed Care Calendar
- AAPM 2010 Clinical Meeting
Poll
Issue
- Issue:February 2010
With Legislation Stalled, Reformers Regroup
Confronted with public opposition, a unified minority party, and an election loss that changed the balance of power in the US Senate, healthcare reform efforts have entered a new phase featuring talk of bipartisan cooperation and a healthcare summit at the White House. Democrats continue to hold majorities in the House of Representatives and the Senate, but after months of debate and several narrowly won votes, their voluminous healthcare bills may no longer be viable. The opposition is calling for reformers to toss out the current Hous
- Issue:February 2010
CMS Report Depicts Government’s Increasing Role
Spending on healthcare in the United States totaled $2.5 trillion in 2009, a 5.7% increase, and accounted for 17.3% of the nation’s gross domestic product (GDP). Although job losses contributed to a reduction in private insurance enrollment, insurers saw better growth in private health insurance premiums than during 2008. Growth in public-sector healthcare spending outpaced increases in private outlays, and the government’s share of the national healthcare bill is projected to exceed 50% by 2012, according to projections rele
- Issue:February 2010
In the discussion of healthcare reform in the United States, primary care physicians have been focused on as the point practitioners in the drive to deliver higher-quality care and to lower costs. Meanwhile, patient populations have increased, growing older and more complex, while net income for primary care physicians dropped by 10.2% between 1995 and 2003. Studies have indicated that greater patient satisfaction is associated with perceived and actual visit duration, and that a poor provider relationship may lead to lesser medication adherence.
The investigators wished to deter
- Issue:February 2010
Philadelphia—Golimumab inhibited progression of radiographic damage to joints in patients with psoriatic arthritis (PSA), according to 52-week results of the randomized, controlled the GO-REVEAL (Golimumab-Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody) study reported at the ACR meeting. Arthur F. Kavanaugh, MD, of the University of California San Diego presented results a late-breaking news session.
Golimumab, an injectable anti-tumor necrosis factor (TNF
- Issue:February 2010
Product Spotlight
Victoza
(liraglutide)Liraglutide (Victoza) is a once-daily injection that treats type 2 diabetes mellitus (T2DM) in adults. The product is in a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists that help the pancreas release more insulin after patients eat a meal. Liraglutide stimulates the release of insulin from the pancreatic beta cells only when blood sugar levels are high.
Along with diet, exercise, and selected other diabetes medicines in adults with T
REQUIP XL is an oral dopamine agonist medication for Parkinson’s disease and had demonstrated significant improvement in the symptoms of Parkinson’s disease.
The Role of Immune Function in the Changing Landscape of RRMS Therapies
Gastroesophageal reflux disease (GERD) is an important
managed care health concern because it is one of the most common gastrointestinal (GI) disorders in the United
States. GERD affects nearly 18.6 million Americans, according to a national healthcare database analysis.
Parkinson’s disease (PD) is a progressive
and disabling neurologic disorder. The disease is the most prevalent type of parkinsonism, a clinical syndrome caused by lesions in the basal ganglia, predominantly in the substantia nigra, which produces deficits in motor behavior.
